Dissecting the Bristol-Myers Dividend
In May, I wrote about the long-term cycle of the big pharma industry and I suggested that, from a technical perspective, several companies in the sector exhibited characteristics of a new, long-term up cycle in which Pfizer (PFE) and Johnson & Johnson (JNJ) present current good value with undervalued dividend-yield profiles.
In light of Bristol-Myers Squibb (BMY) announcing a $3 billion share buyback Tuesday, readers have been asking for a dividend-yield profile....176 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.
There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.
Already a Subscriber? Please login.
